Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-1.5
Face value
--
Shares outstanding
7,504,780
CFO
$-49.78 Mln
EBITDA
$-132.18 Mln
Net Profit
$-139.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioRestorative Therapies Inc (BRTX)
| 18.9 | 5.6 | 1.8 | -23.4 | -22.1 | 16.3 | -62.4 |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
BioRestorative Therapies Inc (BRTX)
| -17.7 | -36.7 | -36.6 | -84.3 | 38.0 | -99.4 | -75.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BioRestorative Therapies Inc (BRTX)
|
1.7 | 12.9 | 0.4 | -12.1 | -1,904.3 | -149.9 | -- | 2.0 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 4.0 | |
| 128.1 | 8,293.4 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 10,095.9 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,385.6 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19 | 5.3 | |
| 302.7 | 8,650.6 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.4 | |
| 25.4 | 10,055.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.3 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.5 | 1.9 |
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The... company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York. Address: 40 Marcus Drive, Melville, NY, United States, 11747 Read more
Chairman of the Board, President & CEO
Mr. Lance Alstodt
Chairman of the Board, President & CEO
Mr. Lance Alstodt
Headquarters
Melville, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of BioRestorative Therapies Inc (BRTX) stood at $ 15 Mln as on 31-Mar-25
The share price of BioRestorative Therapies Inc (BRTX) is $1.70 (NASDAQ) as of 18-Jun-2025 16:27 EDT. BioRestorative Therapies Inc (BRTX) has given a return of -22.13% in the last 3 years.
BioRestorative Therapies Inc (BRTX) has a market capitalisation of $ 13 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of BioRestorative Therapies Inc (BRTX) is 1.98 times as on 18-Jun-2025, a 28% discount to its peers’ median range of 2.75 times.
Since, TTM earnings of BioRestorative Therapies Inc (BRTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioRestorative Therapies Inc (BRTX) and enter the required number of quantities and click on buy to purchase the shares of BioRestorative Therapies Inc (BRTX).
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. It also operates a commercial biocosmeceutical platform. In addition, the company provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York. Address: 40 Marcus Drive, Melville, NY, United States, 11747
The CEO & director of Mr. Lance Alstodt. is BioRestorative Therapies Inc (BRTX), and CFO & Sr. VP is Mr. Lance Alstodt.
There is no promoter pledging in BioRestorative Therapies Inc (BRTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
827
|
|
|
808
|
|
|
742
|
| BioRestorative Therapies Inc (BRTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-149.92
|
|
Operating margin(%)
|
-1904.33
|
|
Net Margin(%)
|
-3093.59
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of BioRestorative Therapies Inc (BRTX) was $0 Mln.
$-0.02
(
